Journal of Breast Cancer

Korean Breast Cancer Society (한국유방암학회)
권호 표지
DOI QR코드

DOI QR Code

miR-195/miR-497 Regulate CD274 Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer

  • Yang, Lianzhou (The 1st Ward of the Medical Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University) ;
  • Cai, Yuchen (State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) ;
  • Zhang, Dongsheng (State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) ;
  • Sun, Jian (State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) ;
  • Xu, Chenyu (The 1st Ward of the Medical Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University) ;
  • Zhao, Wenli (The 1st Ward of the Medical Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University) ;
  • Jiang, Wenqi (State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) ;
  • Pan, Chunhua (The 1st Ward of the Medical Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University)
  • Received : 2018.04.12
  • Accepted : 2018.11.12
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: Immune suppression is common in patients with advanced breast cancer but the mechanisms underlying this phenomenon have not been sufficiently studied. In this study, we aimed to identify B7 family members that were able to predict the immune status of patients, and which may serve as potential targets for the treatment of breast cancer. We also aimed to identify microRNAs that may regulate the expression of B7 family members. Methods: The Cancer Genome Atlas data from 1,092 patients with breast cancer, including gene expression, microRNA expression and survival data, were used for statistical and survival analyses. Polymerase chain reaction and Western blot were used to measure messenger RNA and protein expression, respectively. Luciferase assay was used to investigate direct microRNA target. Results: Bioinformatic analysis predicted that microRNA (miR)-93, miR-195, miR-497, and miR-340 are potential regulators of the immune evasion of breast cancer cells, and that they exert this function by targeting CD274, PDCD1LG2, and NCR3LG1. We chose CD274 for further investigations. We found that miR-195, miR-497, and CD274 expression levels were inversely correlated in MDA-MB-231 cells, and miR-195 and miR-497 expressions mimic inhibited CD274 expression in vitro. Mechanistic investigations demonstrated that miR-195 and miR-497 directly target CD274 3' untranslated region. Conclusion: Our data indicated that the level of B7 family members can predict the prognosis of breast cancer patients, and miR-195/miR-497 regulate CD274 expression in triple negative breast cancer. This regulation may further influence tumor progression and the immune tolerance mechanism in breast cancer and may be able to predict the effect of immunotherapy on patients.

Keywords

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. https://doi.org/10.1002/ijc.29210
  2. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 2016;66:31-42. https://doi.org/10.3322/caac.21320
  3. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol 2014;15:e279-89. https://doi.org/10.1016/S1470-2045(13)70567-9
  4. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 2015;15:321-33. https://doi.org/10.1038/nrc3932
  5. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77. https://doi.org/10.1038/nri2326
  6. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 2016;44:955-72. https://doi.org/10.1016/j.immuni.2016.05.002
  7. Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity 2016;44:1069-78. https://doi.org/10.1016/j.immuni.2016.04.023
  8. Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget 2016;7:45370-84.
  9. Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun 2016;7:11406. https://doi.org/10.1038/ncomms11406
  10. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-40. https://doi.org/10.1093/bioinformatics/btp616
  11. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012;7:e51862. https://doi.org/10.1371/journal.pone.0051862
  12. Gibson J. Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol 2015;16:e264.
  13. Wu R, Li F, Zhu J, Tang R, Qi Q, Zhou X, et al. A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population. Med Oncol 2014;31:60. https://doi.org/10.1007/s12032-014-0060-2
  14. Yuan SM, Li H, Yang M, Zha H, Sun H, Li XR, et al. High intensity focused ultrasound enhances anti-tumor immunity by inhibiting the negative regulatory effect of miR-134 on CD86 in a murine melanoma model. Oncotarget 2015;6:37626-37.
  15. Wu L, Chen Z, Zhang J, Xing Y. Effect of miR-513a-5p on etoposidestimulating B7-H1 expression in retinoblastoma cells. J Huazhong Univ Sci Technolog Med Sci 2012;32:601-6. https://doi.org/10.1007/s11596-012-1004-8
  16. Guo W, Tan W, Liu S, Huang X, Lin J, Liang R, et al. MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumour Biol 2015;36:9049-57. https://doi.org/10.1007/s13277-015-3644-3
  17. Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y, et al. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol 2014;75:348-53. https://doi.org/10.1016/j.humimm.2014.01.006
  18. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241. https://doi.org/10.1038/ncomms6241
  19. Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal 2015;27:443-52. https://doi.org/10.1016/j.cellsig.2014.12.003
  20. Yang P, Tang R, Zhu J, Zou L, Wu R, Zhou H, et al. A functional variant at miR-24 binding site in B7-H2 alters susceptibility to gastric cancer in a Chinese Han population. Mol Immunol 2013;56:98-103. https://doi.org/10.1016/j.molimm.2013.04.010
  21. Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009;69:6275-81. https://doi.org/10.1158/0008-5472.CAN-08-4517
  22. Wang ZS, Zhong M, Bian YH, Mu YF, Qin SL, Yu MH, et al. MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer. Oncotarget 2016;7:44266-76.
  23. Wang L, Kang FB, Sun N, Wang J, Chen W, Li D, et al. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma. Tumour Biol 2016;37:14939-47. https://doi.org/10.1007/s13277-016-5386-2
  24. Zhou X, Mao Y, Zhu J, Meng F, Chen Q, Tao L, et al. TGF-beta1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis. Oncotarget 2016;7:67196-211.
  25. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014;146:15-24. https://doi.org/10.1007/s10549-014-2988-5
  26. Baptista MZ, Sarian LO, Derchain SF, Pinto GA, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol 2016;47:78-84. https://doi.org/10.1016/j.humpath.2015.09.006
  27. Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Menetrier-Caux C. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells. Oncoimmunology 2013;2:e23185. https://doi.org/10.4161/onci.23185
  28. Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, et al. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget 2015;6:3452-61.
  29. Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 2010;252:1044-51. https://doi.org/10.1097/SLA.0b013e3181f1939d
  30. Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, et al. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res 2017;23:825-32. https://doi.org/10.1158/1078-0432.CCR-15-3071

Cited by

  1. The Regulatory Role of MicroRNAs in Breast Cancer vol.20, pp.19, 2018, https://doi.org/10.3390/ijms20194940
  2. Protective effect of HSA‐MIR ‐570‐3p targeting CD274 on triple negative breast cancer by blocking PI3K / AKT / M vol.36, pp.8, 2018, https://doi.org/10.1002/kjm2.12212
  3. MiR-4458/human antigen R (HuR) modulates PBX3 mRNA stability in melanoma tumorigenesis vol.312, pp.9, 2018, https://doi.org/10.1007/s00403-020-02051-8
  4. miR-301b-3p Regulates Breast Cancer Cell Proliferation, Migration, and Invasion by Targeting NR3C2 vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/8810517
  5. hsa_circ_0013401 Accelerates the Growth and Metastasis and Prevents Apoptosis and Autophagy of Neuroblastoma Cells by Sponging miR-195 to Release PAK2 vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/9936154
  6. The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review vol.22, pp.5, 2018, https://doi.org/10.3390/ijms22052652
  7. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis vol.12, pp.4, 2018, https://doi.org/10.3390/genes12040549
  8. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery vol.12, pp.8, 2018, https://doi.org/10.3390/genes12081206
  9. miR‑497/MIR497HG inhibits glioma cell proliferation by targeting CCNE1 and the miR‑588/TUSC1 axis vol.46, pp.6, 2018, https://doi.org/10.3892/or.2021.8206